202 related articles for article (PubMed ID: 28951871)
1. Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.
Koval O; Kochneva G; Tkachenko A; Troitskaya O; Sivolobova G; Grazhdantseva A; Nushtaeva A; Kuligina E; Richter V
Biomed Res Int; 2017; 2017():3620510. PubMed ID: 28951871
[TBL] [Abstract][Full Text] [Related]
2. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
3. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma.
Vasileva N; Ageenko A; Byvakina A; Sen'kova A; Kochneva G; Mishinov S; Richter V; Kuligina E
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673835
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact.
Semenov DV; Vasileva NS; Dymova MA; Mishinov SV; Savinovskaya YI; Ageenko AB; Dome AS; Zinchenko ND; Stepanov GA; Kochneva GV; Richter VA; Kuligina EV
Cells; 2023 Nov; 12(22):. PubMed ID: 37998351
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Inoue T; Byrne T; Inoue M; Tait ME; Wall P; Wang A; Dermyer MR; Laklai H; Binder JJ; Lees C; Hollingsworth R; Maruri-Avidal L; Kirn DH; McDonald DM
Mol Cancer Ther; 2021 Aug; 20(8):1481-1494. PubMed ID: 34045231
[TBL] [Abstract][Full Text] [Related]
8. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
9. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.
Rodr Guez D; Rodr Guez JR; Llorente M; V Zquez I; Lucas P; Esteban M; Mart Nez-A C; Del Real G
J Gen Virol; 1999 Jan; 80 ( Pt 1)():217-223. PubMed ID: 9934705
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
de Vries CR; Monken CE; Lattime EC
Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
[TBL] [Abstract][Full Text] [Related]
12. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.
Timiryasova TM; Chen B; Fodor I
J Gene Med; 2001; 3(5):468-77. PubMed ID: 11601760
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Activity of a Novel Influenza A Virus Carrying Granulocyte-Macrophage Colony-Stimulating Factor in Hepatocellular Carcinoma.
Penghui Y; Fang S; Ruilan W; Guanglin L; Hongjing G; Yueqiang D; Zhongpeng Z; Xiaolan Y; Zhaohai W; Shaogeng Z; Xiliang W
Hum Gene Ther; 2019 Mar; 30(3):330-338. PubMed ID: 30205709
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic vaccinia virus inhibits human hepatocellular carcinoma MHCC97-H cell proliferation via endoplasmic reticulum stress, autophagy and Wnt pathways.
Jia X; Chen Y; Zhao X; Lv C; Yan J
J Gene Med; 2016 Sep; 18(9):211-9. PubMed ID: 27441866
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
[TBL] [Abstract][Full Text] [Related]
17. The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.
Vasileva NS; Ageenko AB; Richter VA; Kuligina EV
Acta Naturae; 2022; 14(2):62-70. PubMed ID: 35923561
[TBL] [Abstract][Full Text] [Related]
18. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
19. Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact.
Dymova MA; Malysheva DO; Popova VK; Dmitrienko EV; Endutkin AV; Drokov DV; Mukhanov VS; Byvakina AA; Kochneva GV; Artyushenko PV; Shchugoreva IA; Rogova AV; Tomilin FN; Kichkailo AS; Richter VA; Kuligina EV
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398600
[TBL] [Abstract][Full Text] [Related]
20. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
